Genentech has planned to invest approximately USD 750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon.a The investment will bring new end-to-end device filling capabilities to the site and expand capacity to support the future pipeline of innovative medicines across Roche and Genentech.

The investment is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs in Oregon during site development, with commercial operations expected to begin in 2031.

The new facility will support the manufacturing of advanced drug delivery devices, such as pre-filled syringes and autoinjectors. These devices play an increasingly important role in how medicines are delivered and can provide patients with more convenient ways to receive treatment outside of a hospital setting.

Designed for flexibility, the facility will be capable of both high- and low-volume device filling across a broad range of Roche and Genentech’s portfolio, enabling the site to respond to changing manufacturing needs as the portfolio evolves.

The Hillsboro investment follows the recent topping out of Genentech’s new manufacturing facility in Holly Springs, North Carolina, a facility strategically designed to support global production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.

Roche and Genentech’s current US footprint includes 13 manufacturing sites, 15 research and development (R&D) sites and approximately 25,000 employees across 24 locations in 8 states.